What is the appropriate eight‑week prednisolone taper regimen for a patient with alcoholic hepatitis who has a Lille score <0.45 at day 7?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Eight-Week Prednisolone Taper Regimen for Alcoholic Hepatitis with Lille Score <0.45

For patients with alcoholic hepatitis who respond to treatment (Lille score <0.45 at day 7), continue prednisolone 40 mg daily for a total of 28 days, then either stop abruptly or taper over 2-3 weeks—there is no established 8-week regimen supported by current guidelines. 1

Standard Treatment Duration and Tapering

The EASL 2018 guidelines explicitly state that prednisolone 40 mg/day (or methylprednisolone 32 mg/day) should be prescribed for 28 days total in responders 1. At the end of this 4-week course, you have two evidence-based options:

  • Abrupt discontinuation after 28 days
  • Gradual taper over 3 weeks (reducing the total treatment exposure to approximately 7 weeks, not 8) 1

The French guidelines (2022) align with this approach, confirming that treatment duration is 28 days for responders 2.

Why Not 8 Weeks?

An 8-week regimen is not standard for alcoholic hepatitis. The evidence base for corticosteroids shows:

  • Benefit is limited to the first 28 days only 1
  • Prednisolone provides no survival benefit beyond one month, confirmed by network meta-analysis 1
  • Prolonged steroid exposure increases infection risk without additional benefit 3

Practical Tapering Approach

If you choose to taper (rather than stop abruptly), the most commonly reported regimen is:

Week 5-6 (2-week taper):

  • Reduce by 10 mg every 3-4 days
  • Example: 40 mg → 30 mg → 20 mg → 10 mg → stop
  • This is the most frequently used taper duration in clinical trials 4

Alternative 3-week taper 1:

  • Week 5: 30 mg daily
  • Week 6: 20 mg daily
  • Week 7: 10 mg daily
  • Week 8: Stop

Recent Evidence on Tapering

A 2025 randomized trial (STASH) compared standard fixed-dose (40 mg × 28 days) versus a 4-week tapered regimen (40 mg tapered by 10 mg weekly) 3. Key findings:

  • Tapered dosing reduced infection rates: 19.7% vs 33.1% (HR 0.57, p=0.03)
  • No difference in mortality, AKI, or readmissions
  • Microbiologically proven infections: 8.6% vs 19% (p=0.02)

This suggests that shorter steroid exposure may be safer without compromising efficacy.

Critical Monitoring Points

During any taper period:

  • Most infections occur in the first month 4
  • Monitor closely for infection, GI bleeding, and renal impairment 4
  • Ensure close outpatient follow-up after discharge 4
  • The Lille score at day 7 remains the key decision point—if ≥0.45, stop steroids immediately (especially if ≥0.56) 1, 2

Common Pitfall

Do not confuse alcoholic hepatitis protocols with autoimmune hepatitis, where longer steroid courses (months to years) are standard 5, 6, 7. These are entirely different diseases with different treatment paradigms.

Bottom Line Algorithm

  1. Day 7: Calculate Lille score
  2. If Lille <0.45: Continue prednisolone 40 mg daily through day 28
  3. Day 28: Either stop abruptly OR begin 2-week taper (10 mg reduction every 3-4 days)
  4. Total duration: 28 days (abrupt stop) or 42 days (6 weeks with taper)

An 8-week regimen has no evidence base and unnecessarily prolongs infection risk.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.